Detection and early warning solves spread
Borja et. al. 20- postdoctoral research fellow at the Center for Global Security Research (CGSR) at Lawrence Livermore National Laboratory AND** Fellow at the Center for Global Security Research (CGSR) AND** research associate at the Center for Global Security Research (CGSR) at Lawrence Livermore National Laboratory AND** postdoctoral research fellow at the Center for Global Search Research AND** postdoctoral research fellow at the Center for Global Security Research (CGSR) (Lauren, Alexander Campbell, Marigny Kirschke-Schwartz, Brian Radzinsky, Brandon Williams, “Rethinking U.S. Biosecurity Strategy for the Decade Ahead (Workshop Summary),” Center for Global Security Research, 10-29-20, Accessed Online at https://www.osti.gov/servlets/purl/1735810, Accessed Online on 6-21-22)
Biological threats are inherently difficult to calibrate. In the natural environment, emerging and re-emerging pathogens are constantly evolving and spread opportunistically. The intentions and capabilities of human actors to exploit biological agents for purposes of terrorism and war are also in flux as advancing biotechnologies enable both state and nonstate actors to develop new threats. Thus, bio surprise is inevitable, even when the risk is generally acknowledged. Following the initial surprise, rapid detection and assessment are critical to staying ahead of the threat. a. Looking ahead a decade, emerging infectious diseases will likely intensify. A combination of factors, including increased human encroachment into remote habitats and the effects of global warming, can be expected to increase the frequency of epidemics and pandemics. Participants agreed that the United States does not have the luxury of preparing for one or the other (naturally-occurring or man-made); it must be prepared for both. b. Early warning can make a huge difference in mitigating human and other consequences. This requires broad surveillance, reliable information, and broad information sharing. The United States and the international community have multiple capabilities in place to look for early warning signs of an emerging public health crisis, but these depend on a high degree of scientific competence and credibility. Both have diminished in recent years or have failed to adapt in the face of growing political and societal challenges to authority and expertise. Divestment, disinformation, and outright attacks have all been contributing factors. c. With early indicators in hand, the role of the scientific community is to out-race the unfolding public health crisis by rapidly characterizing the biological source, openly sharing epidemiological data, implementing public health measures (such as maskwearing, contact tracing, and isolating the sick), and developing medical therapeutics. The ability to do these has greatly advanced in recent years, with improved international cooperation within the scientific community a contributing factor. The potential pathways to medical solutions have also increased significantly (e.g., there are currently 44 vaccines for COVID-19 in clinical evaluation and another 154 in preclinical stages). 3. Looking to the future, specific actions should be in place to enable an effective crisis response. This includes steps to enable the rapid production and deployment of diagnostic tests, monoclonal antibodies, antivirals, and anti-inflammatory drugs. It also includes steps to maintain a capacity for large-scale development and production of vaccines and new therapeutic drugs. In addition, better predictive models would improve the analysis of alternative interventions; however, these models require access to well curated and prepositioned data sets. A key challenge in accelerating responses by the medical research community is the improved use of research that has not yet been peer reviewed; some innovative mechanisms to rapidly review, assess, and make available worthy research are now up and running. 4. In addition, many of the global and regional partnerships needed to respond effectively have not worked as desired during COVID-19 and are in need of repair. These partnerships include the following: public-private, public health-national security, medical-law enforcement, U.S.- allies, international organizations-member states, government-news media, elements of the supply chain, etc. 3 5. To a significant extent, further revisions to national strategy will be driven by lessons learned from the COVID-19 epidemic. As the pandemic tapers off, governmental attention and funding are likely to remain high—for a while. If the past is any guide, however, other demands will emerge, and both attention and funding will decline. Given the expectation of an increased frequency of public health crises in the future, specific actions should be taken now while there is increased funding and public attention on the problem. a. Successful management of a health crisis requires a whole of government response. Essential capabilities include the ability to rapidly get all stakeholders to the table, generate reliable data, quickly define required decisions and make them, rapidly identify and cope with unexpected facets of the problem, coordinate the distribution of limited resources, and coordinate implementation activities across state, federal, and local lines. They also include the ability to manage the domestic and international political dimensions of a situation, rather than try to pretend that a public health crisis is not a political event. The opportunity to learn and practice these skills will improve their efficacy during a crisis. b. Communicating effectively in crisis is an especially important skill. Past crises have repeatedly taught a lesson about the importance of communicating with empathy. This means telling the truth, providing hope, setting expectations, and being explicit about “the ask” of the audience. c. Much more can be done both nationally and internationally to strengthen existing capacities and add new capabilities. Significant gaps remain in the global architecture of institutions and processes for managing biological risks, whether naturally occurring or man-made. d. The United States should also learn from the successes of its COVID-19 response, particularly those from Operation Warp speed. Many panelists commented that the speed by which vaccine candidates have advanced to clinical trials was amazing. This success story demonstrates how the U.S. government can help underwrite cost and risk of new vaccine development for pharmaceutical companies.